VieCure Launches Pilot Program with Clarified Precision Medicine at ALCC to Accelerate the Adoption of Precision Oncology
With a focus on Patients and Community Oncologists, the Partners will Turn a Greater Number of Molecular Test Results Into Actionable Therapy
VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists. In recent years there has been a large shift towards the use of patient-specific cancer treatment options that respond specifically to the molecular profile of the cancer (e.g., genomic data). These data points are complex, considerable, and difficult to access at the community oncology level based in part on the changing / updated tumor response data. This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts. This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision as part of the decision-making process for clinicians.
AiThority Interview Insights: AiThority Interview with Alex Mans, Founder and CEO at FLYR Lab
“We are excited about embedding our expertise to further accelerate the adoption of precision oncology and help more patients and providers over the next several years”
VieCure will fully integrate the Clarified Precision Medicine Somatic and Germline Clinical Consultation process within its artificial intelligence platform and offer community oncologists streamlined access to Clarified’s nationally recognized test interpretation team. These professionals will function as elastic / on-demand supply for the clinical providers on the ground who are working tirelessly every day to help cancer patients and offer them with the best patient-specific options possible. Clarified Precision Medicine has also developed additional tools which help providers manage toxicities, optimize supportive care, and improve overall clinical efficiency.
The VieCure-Clarified partnership offers a precision oncology expert consideration, where elite, expert precision medicine guidance can be accessed while using the VieCure clinical decision support platform. “We are excited about embedding our expertise to further accelerate the adoption of precision oncology and help more patients and providers over the next several years,” said Dr. Howard McLeod, a nationally-recognized Precision Oncology expert.
Read More about AiThority Interview: AiThority Interview with Elliott Jobe, Chief Innovation Officer and Co-Founder at Infinite Reality
VieCure will integrate the Clarified Medicine Precision testing tools within its platform and make the Clarified offering available to oncologists and clinical users later this year. Oncologists using the VieCure platform will be able to order their molecular test (e.g., next generation tumor sequencing) directly out of the VieCure platform and then obtain their precision medicine review within 48 hours following three easy steps:
- VieCure’s platform ingests discrete molecular test results for review and interpretation.
- Clarified Precision Medicine’s clinical experts will review the molecular test results.
- Upon receipt of the molecular test results, the clinical provider will receive an easy-to-understand report condensing the patient’s results into a ranked list of treatment options (including clinical trials) and suggestions about any additional testing, if necessary, directly within the VieCure platform. Furthermore, the provider also has the ability to connect with the Clarified Precision Medicine expert to discuss the results as needed.
VieCure will launch a pilot program at Alabama Cancer Care, granting early access to the ClarifiedSelect Report embedded in the VieCure platform. This is a tremendous step to improve access to next-generation cancer care for all and help ensure cancer patients live their best lives.
“VieCure and Clarified Precision Medicine, together, are further democratizing precision oncology and making it easier for community oncologists to offer the right care for the right patient every time,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure.
Latest AiThority Interview Insights : AiThority Interview with Dorian Selz, Co-Founder & CEO at Squirro
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.